Savara Stock (NASDAQ:SVRA)
Previous Close
$2.60
52W Range
$2.25 - $5.34
50D Avg
$2.81
200D Avg
$3.70
Market Cap
$446.21M
Avg Vol (3M)
$937.32K
Beta
0.59
Div Yield
-
SVRA Company Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DYN | Dyne Therapeutics, Inc. |
| GPCR | Structure Therapeutics Inc. |
| ANAB | AnaptysBio, Inc. |
| XOMA | XOMA Corporation |
| FENC | Fennec Pharmaceuticals Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| KZR | Kezar Life Sciences, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| SRRK | Scholar Rock Holding Corporation |
| TARA | Protara Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| VACC | Barinthus Biotherapeutics plc |